Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

The article presents a randomised, double-blind study which compares denosumab with zoledronic acid for prevention and treatment of skeletal-related events in male patients with bone metastases from castration-resistant prostate cancer. An interactive voice response system was employed to assign patients to receive certain dosage of one of the two drugs. The study concludes that denosumab is better than zoledronic acid in preventing skeletal-related events.